It has been announced that The Clatterbridge Cancer Centre will be the lead site in the UK for a worldwide trial of a new drug for people suffering from a form of liver cancer.
Hepatocellular-Carcinoma (HCC) is a form of liver cancer that has seen a rapid increase over the last 30 years, with the number of cases tripling largely due to lifestyle factors such as alcohol consumption, obesity and type 2 diabetes.
The new drug will be administered to patients taking part in the trial at The Clatterbridge Cancer Centre every two weeks, for up to two years.
Explaining the new drug trial, Dan Palmer, Chair of Medical Oncology and the trial lead at The Clatterbridge Cancer Centre, said: “HCC has a tendency to grow and develop undetected by the immune system, meaning it’s usually in the latter stages of the disease when a patient starts to present symptoms. By using this new treatment, we’re looking to ‘remove the cloak’ from the cancer cells, so they can become recognisable to the immune system and the body has the ability to fight them. It has the potential to be extremely powerful with this particular cancer and we’re very excited to be able to start monitoring its progress at The Clatterbridge Cancer Centre and hope to be able to open new doors for some of our patients.”
For more information, please visit the website.
